Sichuan Science and Technology Innovation Investment Group
四川科创投集团
Sichuan Science and Technology Innovation Investment Group (四川科创投集团) shows up in elsewhere's corpus only in one capacity: as an existing shareholder that continued to back Zenitar (赜灵生物) in the company's nearly RMB 600 million Series C round announced in January 2026 — a round co-led by Temasek's Danming Capital and Qiming Venture Partners, per Qiming's and BlueRun Ventures' announcements . That participation marks it as an investor in Chinese biotech, but elsewhere's corpus does not otherwise profile the group — its founding details, fund size, or broader strategy aren't covered.
AI-generated — may contain errors, please verify.
Coverage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
Qiming Venture Partners co-leads Zenitar's nearly 600 million yuan Series C round
late-stage clinical biotech company
